• Blog
  • Divalproex Sodium Market Report

    Divalproex Sodium Market Report

    Divalproex Sodium Market Report
    Report code - SR1151 Delivery - 2 Weeks
    Global Divalproex Sodium Market, Dynamics, Trends, Market Analysis
    See more...

    Market Insights

    The global divalproex sodium market is estimated to grow from USD 2.37 billion in 2022 to USD 3.38 billion by 2028 at a healthy CAGR of 6.04% during the forecast period.

    divalproex-sodium-market-size

    Wish to get a free scope on this study? Click here.

    What is divalproex sodium?

    Divalproex sodium is a Food and Drug Administrator (FDA) approved anti-epileptic drug which is used to treat migraine headaches, certain types of seizures, and manic episodes of bipolar disorders. It is widely known for its anti-convulsant properties for the treatment of epilepsy. It is also used in various combinational therapies.

    Global Divalproex Sodium Market Report Overview

    Market Size in 2023

    USD 2.52 billion

    Market Size in 2028

    USD 3.38 billion

    Market Growth (2023-2028)

    CAGR of 6.04%

    Base Year of Study

    2022

    Trend Period

    2017-2021

    Forecast Period

    2023-2028

    Key Players

    Key players operating in the global divalproex sodium market are-

    • AbbVie (The U.S),
    • Mylan, Zydus Pharms USA,
    • Aurobindo Pharma (India),
    • Dr Reddys Labs (India),
    • LUPIN (India),
    • Orchid (India),
    • Sun Pharm (India), and
    • Teva (Israel).

    Market Dynamics

    Growing prevalence of bipolar disorders across the globe is augmenting the market growth.

    • Also, the increasing patient pool across the globe affected the migraine and epilepsy headaches, thus propelling the product demand.
    • In addition, rising awareness towards diseases and several government initiatives to prevent head migraine is likely to boost the industry growth during the review period.

    Segment's Analysis

    Form Trends

    Based on form, the divalproex sodium market is classified into Capsule, Tablet, Syrup.

    • The tablet segment is expected to hold the largest share in this market segment during the forecast period.
    • Divalproex sodium oral tablet, also known as Depakote ER and Depakote, is used in various combinational therapies for treating bipolar disorders, complex partial seizures, and migraine headaches.
    • The recommended initial dosage is 750 mg daily, with complex partial seizures starting at 10 to 15 mg/kg/day. Extended-release tablets, valproate, are used for acute manic or mixed episodes associated with bipolar disorder.
    • Tablets are more shelf-stable and have a longer shelf life than capsules, making them ideal for treatments requiring a greater dosage.

    Application Trends

    Based on application, the divalproex sodium market is classified into epilepsy, manic depressive illness, and others.

    • The epilepsy segment held a significant share in 2022 and is projected to grow at the highest CAGR during the assessment period.
    • This is mainly attributed to rising prevalence of epilepsy among kids and adults.
    • Also, as per WHO 2018 facts, around 50 million people were globally affected with epilepsy and around 80% of the people with epilepsy live in low- and middle-income countries which further bolsters the segment growth.

    Regional Trends

    By region, the North America market accounted for the largest share in 2022 and is expected to grow at a substantial CAGR in the following years.

    • This is mainly ascribed to rising government initiatives and increasing research & development for the introduction of new product are expected to aid in growth of the divalproex sodium market in the region.
    • In addition, strong healthcare infrastructure, increasing healthcare expenditure, and supportive reimbursement policies, further proliferates the regional market growth.

    divalproex-sodium-market-regional-insights

    Wish to know more about the study? Click here

    COVID-19 Impact

    The COVID-19 outbreak has moderately affected the divalproex sodium industry. This is mainly attributed to shift of medical care towards coronavirus infected patients. However, rising cases of bipolar disorder due to stress during the pandemic, is expected to surge the product demand amid the pandemic.

    Critical Questions Answered in the Report

    • What are the key trends in the divalproex sodium market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the divalproex sodium market?
    • What are the key strategies adopted by the major vendors to lead in the market?
    • What is the market share of the top vendors?

    Target Audience

    Here is the list of the group of customers that the Divalproex Sodium market hopes to have the greatest opportunity to convert-

    • Divalproex sodium vendors
    • Divalproex sodium retailers
    • Epilepsy organizations
    • Psychiatrists

     

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The divalproex sodium market size is expected to reach USD 3.38 billion in the foreseeable future.

    AbbVie (The U.S), Mylan, Zydus Pharms USA, Aurobindo Pharma (India), Dr Reddys Labs (India), LUPIN (India), Orchid (India), Sun Pharm (India) and Teva (Israel) are among the key players in the market.

    The divalproex sodium market is expected to witness an impressive growth of 6.04% CAGR in the coming years.

    The epilepsy segment is expected to grow at the highest CAGR in the market in the coming years.

    North America market accounted for the largest share in 2022 and is expected to grow at a substantial CAGR.

    Divalproex sodium vendors, Divalproex sodium retailers, Epilepsy organizations, Psychiatrists are the target audience in the market.